CORE--Analytical and Genotyping

核心——分析和基因分型

• 批准号: 7310960
• 负责人: Janine G Einspahr
• 金额: $ 49.35万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7310960
• 关键词: adenomatous polyps; automated data processing; biomedical facility; colorectal neoplasms; data quality /integrity; drug metabolism; gene expression; genetic polymorphism; genetic registry /resource /referral center; genetic screening; genetic susceptibility; genotype; human genetic material tag; human tissue; method development; neoplasm /cancer genetics; nonsteroidal antiinflammatory agent; oxidoreductase inhibitor; pharmacogenetics; prostaglandin endoperoxide synthase; sample collection; selenium; tissue /cell preparation; tissue resource /registry; training

Analytical will serve as a collection and distribution point for blood samples, DMA, original clinical pathology slides, and colorectal polyp tissue blocks. It will provide a resource and service for carrying out the laboratory analyses proposed in this application. We will develop appropriate sample collection, tracking, storage, and preparation procedures for all biologic samples collected during the course of this proposal. It will develop and optimize methods of measuring the laboratory research endpoints. Analytical will be responsible for the collection, logging, processing, distribution, and tracking of all tissues and samples. Endpoints to be analyzed include blood levels of the treatment drugs, celecoxib and selenium, and COX-2 expression in colorectal polyps. Analytical will oversee and coordinate the collection and processing of all samples related to this Program Project at the various participating hospitals and clinics Furthermore, we will be responsible for the training of personnel involved in the collection and processing of study samples. We will manage the pathology review of all polyp tissue included within this proposal. It will perform work closely with Biometry to provide data for reporting and interpretation. Quality assurance and quality control procedures will continue to be developed in collaboration with Biometry for sample acquisition, processing, and analysis procedures included in each of the clinical projects. Genotyping will support the genotyping needs. We will work with the leaders and co-leaders in testing the hypothesis that genetic polymorphisms (1) play a role in the response of individuals to celecoxib and/or selenium treatment and (2) confer increased susceptibility to advanced and/or recurrent colorectal adenomas and colorectal neoplasia. The goals will be achieved through the development and design of assays against both known functional polymorphisms and yet to be identified functional polymorphisms via haplotype analysis. We will efficiently track DMA samples, provide quality control and assurance, perform genetic analyses, and provide data management of the genotyping databases.

分析将作为血液样本，DMA，原始临床病理载玻片和结直肠息肉组织块的收集和分布点。它将提供资源和服务，以进行本应用程序中提出的实验室分析。我们将为所有生物样品开发适当的样品收集，跟踪，存储和准备程序 在此提案过程中收集。它将开发并优化测量实验室研究终点的方法。分析将负责收集，记录， 所有组织和样品的处理，分布和跟踪。要分析的终点包括治疗药物的血液水平，塞来昔布和硒以及Cox-2在 结直肠息肉。分析将监督和协调所有人的收集和处理 与该计划项目有关的样本在各种参与的医院和诊所中，我们还将负责培训参与研究样本的收集和处理的人员。我们将管理该提案中包含的所有息肉组织的病理评论。它将与生物特征进行紧密合作，以提供用于报告和解释的数据。质量保证和质量控制程序将继续开发 与生物特征的合作，以获取样本，处理和分析程序，包括每个临床项目。基因分型将支持基因分型需求。 我们将与领导者和共同领导者合作，以测试遗传多态性（1）在个体对Celecoxib和/或硒治疗的反应中起作用的假设，以及（2）赋予对先进和/或复发性结直肠的敏感性增加 腺瘤和结直肠肿瘤。目标将通过开发实现， 针对已知功能多态性的测定法设计，尚未通过单倍型分析鉴定出功能性多态性。我们将有效地跟踪DMA样本，提供质量控制和保证，进行遗传分析并提供基因分型数据库的数据管理。